To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Proteasome inhibitorProteasome inhibitors are drugs that block the action of proteasomes, cellular complexes that break down proteins, like the p53 protein. Proteasome inhibitors are being studied in the treatment of cancer. In 2003, bortezomib was the first proteasome inhibitor to be approved for use in the U.S. Additional recommended knowledgeA derivative of epigallocatechin-3-gallate has been proposed as another proteasome inhibitor.[1] References
Categories: Chemotherapeutic agents | Inhibitors |
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Proteasome_inhibitor". A list of authors is available in Wikipedia. |
- Tyrosine_kinase
- World's leading genomics scientists, Brenner, Lander and Venter, receive Novartis Drew University award
- Non-Invasive Imaging Tools May Help Unravel Mechanisms of Prenatal Drug Damage - Technique may also help assess, improve effectiveness of pain medication following fetal surgery
- Merck and Idemitsu Sign Collaboration Agreement in the OLED Material Business
- Pharmaceutical_industry_in_China